Member Info for inanaco

""" There is an obvious gulf between the two. We do not have the track record in viral vaccines """

how long does BioNtech take to build MRNA vaccines against Cancer .... ?

How long did it take against a virus .............

both program the immune system

NO DIFFERENCE ............ its just a target

don't fall into the same trap as other's that the science is somehow separate .. it is NOT

the immune system has exactly the same system in place to deal with both threats but the Cancer side is far more difficult

requiring the most potent and effective vaccines

Indeed the run of the mill viral vaccine for the Flu etc .... is a vaccine with inactive and weakened viral forms.

""At least seven teams are developing vaccines using the virus itself, in a weakened or inactivated form. Many existing vaccines are made in this way, such as those against measles and polio, but they require extensive safety testing. Sinovac Biotech in Beijing has started to test an inactivated version of SARS-CoV-2 in humans.""

the reason Why DNA, MRNA and Virus carriers are used is because of Speed and safety ...

sounds like "Happy Hour is back" this week

but rather than downing two pints of Guinness ..

some have taken to the "Green Slime" as advocated by vegans ....

well i am not debating ....

so that leaves just you

out of interest Ruck i did not reply as you said many would debate ....... they did not

now in Context ... ie CH made statements in a Broad explanation of Scancell as a presentation

you have taken that as absolute Black and white statement .... when its not

as clearly we may have deals shortly without trials ... indeed SCIB2 is being funded before a trial ..

nothing to debate

Ch said it ...
you repeated it

The Original was in context ...

yours is not

I won’t give my own opinion .... But Ch ...

agree he has already told us ...

But for some reason you feel you have discovered something to tell us again ...

Thanks for the info

And ?

what was the result of no real interest ?

apart from the collaborations

scib2

Karolinska

maybe you should Bore somebody else

bearing in mind that the Uni is behind scancell ... just worth looking at some of the Kit ....

https://www.nottingham.ac.uk/nmrc/facilities/emsuite/electronmicroscopysuite.aspx

Max

what do you think this is ................ https://www.scancell.co.uk/monoclonal-antibody-targeting-sialyl-di-lewisa%E2%80%93-containing-internalizing-and-noninternalizing-glycoproteins-with-cancer-immunotherapy-development-potential

""""we validated payload delivery by CH129 through monomethyl auristatin E (MMAE) or maytansinoid (DM1 and DM4) conjugation. All three CH129 drug conjugates killed high-binding colorectal and pancreatic cancer cell lines with (sub)nanomolar potency, coinciding with significant in vivo xenograft tumor control by CH129-vcMMAE. CH129, with its restricted normal tissue distribution, avid tumor binding, and efficient payload delivery, is a promising candidate for the treatment of sialyl-di-Lewisa– expressing solid tumors, as an antibody–drug conjugate or as an alternative cancer immunotherapy modality. """"

the scientific papers once published highlight exactly what is going on, we just have to wait until one of them turns commercial with the collaborations already signed . Now i did highlight from the last RNS """They are also being developed as antibody-drug conjugates (ADC)"""" well that link refers to this scientific paper

Cars
sorry i think you misunderstood why i add avidmab

its because the vaccines that are targeting the spike protein and the importance of high avidity induced by a vaccine

it was not because we need to use avidmab ... its the principle that the binding area of both the T cell and the antibody need to be of High Avidity .. of which scancell has the skill in both

https://www.telegraph.co.uk/health-fitness/body/dislocated-hip-pain-bad-thought-taking-life/

what a story ........

Hip broken up !! ........ cannot get it repaired

disease ... LOL

the point i am making .......... the vaccine could make it worse

ie you still get the infection but its effect is now mild in the majority .. as per the Primates in the oxford trial ....

but they can still spread the decease ..................... ouch ! and the vaccine could do more harm than good in the older generation

Needs to be split into two groups ...........

The mild ... which is the majority .......... they Do Not Matter .... !!

and the Boris level ... those that continue to get worse requiring high level intervention ............

make no mistake without intervention the Virus would have killed Boris

Recent studies of antibody responses in patients with COVID-19 have associated higher titres of anti-N IgM and IgG at all time points following the onset of symptoms with a worse disease outcome16. Moreover, higher titres of anti-S and anti-N IgG and IgM correlate with worse clinical readouts and older age suggesting potentially detrimental effects of antibodies in some patients. However, 70% of patients who recovered from mild COVID-19 had measurable neutralizing antibodies that persisted upon revisit to the hospital18.

https://www.nature.com/articles/s41577-020-0321-6

what i am trying to get across here .......... just having an antibody vaccine like Oxford that could be effective for the young but actually detrimental for the aged ..... The rush to produce a vaccine that fits all ....... could actually be counter productive if given to the entire population ......... Don't forget the T cell counts DROP ........in this group

The NAbs titers in patients were also observed to be correlated with the age of the
patients. Elderly patients had significantly higher titers of NAbs than younger patients.
Age has been reported as an important predictor of adverse disease outcome after
infection with coronavirus, including SARS-CoV20, MERS-CoV21 and SARS-CoV212 311 .
Previous studies in SARS-CoV-infected macaques revealed that aged macaques
313 induced elevated innate immune response, resulting in more severe pathology than
young adult macaques22 314 . The elderly patients in this cohort also had higher blood CRP
level and lower lymphocyte counts at the time of admission, indicating the induction of
stronger innate immune response than younger patients. High level of NAbs may be a
result of strong immune response in these elderly patients. Whether the high level of
NAbs protect these patients from progression into severe and critical conditions is
worthy of comprehensive evaluation. Further study of the immunological
characteristics of COVID-19 patients may reveal key determinants in the generation of
NAbs and effective cell-mediated immune responses, which is important for the
development of an effective vaccine against SARS-CoV-2 virus.

https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v1.full.pdf

https://onlinelibrary.wiley.com/doi/epdf/10.1111/resp.13852

""""but also the possibility that some individuals might have antibodies that could enhance disease pathogenesis"""

older age,16,17these characteristicsof IgG antibody function might be age-related risk factorsfor COVID-19 (Fig. 1) and require investigation.In conclusion, assessment of antibodies to SARS-CoV-2 should take into consideration potential differ-ences in functional effects and diagnostic utility(Table 1). For example, considerations of whether peo-ple who have recovered from COVID-19 have immu-nity to SARS-CoV-2 and should be issued with an‘immunity passport’ (https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19) should not only consider evidencethat serum SARS-CoV-2 antibodies have variable neu-tralization activity,18but also the possibility that someindividuals might have antibodies that could enhancedisease pathogenesis.